Akero Therapeutics, Inc. $AKRO is B Group Inc.’s 4th Largest Position

B Group Inc. lowered its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 4.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 232,446 shares of the company’s stock after selling 10,054 shares during the period. Akero Therapeutics accounts for 9.5% of B Group Inc.’s investment portfolio, making the stock its 4th largest position. B Group Inc.’s holdings in Akero Therapeutics were worth $12,403,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new position in shares of Akero Therapeutics during the 1st quarter worth $21,333,000. Vanguard Group Inc. increased its position in Akero Therapeutics by 14.2% during the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company’s stock worth $171,256,000 after purchasing an additional 526,233 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Akero Therapeutics by 11.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company’s stock worth $194,997,000 after purchasing an additional 495,119 shares during the period. EcoR1 Capital LLC acquired a new position in Akero Therapeutics in the 1st quarter valued at about $17,811,000. Finally, Nuveen LLC purchased a new stake in shares of Akero Therapeutics in the 1st quarter valued at approximately $12,481,000.

Insider Activity at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 12,500 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $47.76, for a total value of $597,000.00. Following the sale, the chief operating officer owned 196,898 shares of the company’s stock, valued at $9,403,848.48. This trade represents a 5.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO William Richard White sold 659 shares of the business’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $43.02, for a total value of $28,350.18. Following the transaction, the chief financial officer directly owned 57,752 shares of the company’s stock, valued at approximately $2,484,491.04. This represents a 1.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 89,253 shares of company stock worth $4,272,864 over the last quarter. 7.07% of the stock is currently owned by insiders.

Akero Therapeutics Price Performance

NASDAQ AKRO opened at $54.65 on Tuesday. The company has a market cap of $4.50 billion, a P/E ratio of -28.17 and a beta of -0.40. The stock has a 50-day moving average of $53.06 and a two-hundred day moving average of $50.88. Akero Therapeutics, Inc. has a 1-year low of $21.34 and a 1-year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.05). On average, analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analysts Set New Price Targets

AKRO has been the topic of a number of recent analyst reports. Wolfe Research cut Akero Therapeutics from an “outperform” rating to a “hold” rating in a report on Friday, October 10th. HC Wainwright restated a “neutral” rating and issued a $54.00 target price (down previously from $72.00) on shares of Akero Therapeutics in a research report on Friday, October 10th. Zacks Research cut Akero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 10th. TD Cowen downgraded Akero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 10th. Finally, Jefferies Financial Group cut shares of Akero Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $75.00 to $56.00 in a research report on Thursday, October 9th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $73.38.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.